Sam Fazeli

Great, thank you.

So Mark, I want to ask you very quickly to answer a question as simply as you can, and then move on to the drug areas or therapeutic areas where you think Xero would be focused on going forward.

And then also tell me where you would hope

you would be, when you would be able to file an IND, or how many you expect.

It's a whole bunch of questions in terms of future looking.

First question is though, your 12 years approval, target to approval, how much can we shave off that?

Just an estimate.

And then talk to me about, please, the therapeutic areas that Zara is going to be focused on, if you've decided already.

and also when you think that you might be in a position to file at least the first IND.

And then, of course, everybody says, we're going to file an IND, three INDs a year.

You know, those sort of pontifications I'd love to hear, if you want to make them.

Okay, thanks, Mark.

I mean, look, we've been talking for coming up to about an hour.

So that's very generous of you.

And I know I was a bit late.

I apologize again.

Do you want to say some final words here?

I mean, I can keep talking to you about this subject and keep drilling and drilling and drilling.

But let me just give you the opportunity to wrap this up.

And you've been involved in drug development for years.